Last quarter (Q4 2023), Lantern Pharma's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Lantern Pharma's net income was $-4.19M. See Lantern Pharma’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	-	-	-	-	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ 9.31M	$ 17.88M	$ 14.43M	$ 12.59M	$ 5.91M	$ 2.43M
Operating Income	$ -9.31M	$ -17.88M	$ -14.43M	$ -12.59M	$ -5.91M	$ -2.43M
Net Non Operating Interest Income Expense	$ 765.39K	$ 765.39K	$ 204.35K	$ 67.93K	$ 0.00	-
Other Income Expense	$ -1.15M	$ -1.15M	$ 31.55K	$ -160.55K	-	-
Pretax Income	$ -7.39M	$ -15.96M	$ -14.26M	$ -12.36M	$ -5.91M	$ -2.43M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -7.39M	$ -15.96M	$ -14.26M	$ -12.36M	$ -5.91M	$ -2.43M
Basic EPS	$ -1.48	$ -1.47	$ -1.31	$ -1.13	$ -1.37	$ -0.39
Diluted EPS	$ -1.48	$ -1.47	$ -1.31	$ -1.13	$ -1.37	$ -0.39
Basic Average Shares	$ 43.37M	$ 10.84M	$ 10.85M	$ 10.90M	$ 4.30M	$ 6.22M
Diluted Average Shares	$ 43.37M	$ 10.84M	$ 10.85M	$ 10.90M	$ 4.30M	$ 6.22M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 9.31M	$ 17.88M	$ 14.43M	$ 12.59M	$ 5.91M	$ 2.43M
Net Income From Continuing And Discontinued Operation	$ -15.96M	$ -15.96M	$ -14.26M	$ -12.36M	$ -5.91M	$ -2.43M
Normalized Income	$ -5.80M	$ -12.61M	$ -11.27M	-	$ -5.91M	$ -2.43M
Interest Expense	-	-	-	-	-	-
EBIT	$ -7.39M	$ -15.96M	$ -14.26M	$ -12.36M	$ -5.91M	$ -2.43M
EBITDA	$ -7.37M	$ -15.95M	$ -14.17M	$ -12.22M	$ -5.90M	$ -2.43M

Currency in USD

Lantern Pharma Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing